Business Context and Reporting Period
This Form 8-K, dated June 28, 2026, reports that Zymeworks Inc. (the "Parent") entered into an Agreement and Plan of Merger with Theravance Biopharma, Inc. (the "Company"). Under the agreement, a wholly-owned subsidiary of Zymeworks will merge with Theravance, with Theravance surviving as a wholly-owned subsidiary of Zymeworks. The transaction is expected to close in the second half of 2026.
Key Financial Metrics and Transaction Terms
- Consideration: Theravance shareholders will receive $17.00 in cash per share plus one Contingent Value Right (CVR).
- Financing: Zymeworks expects to finance the merger using cash on hand and new debt financing. A commitment letter dated June 28, 2026, secures $350,000,000 in senior secured notes from OMERS Life Sciences.
- Termination Fees: A termination fee of $32,515,000 is payable by Theravance to Zymeworks in specific scenarios (e.g., accepting a superior proposal). A reverse termination fee of $32,515,000 is payable by Zymeworks to Theravance if the merger fails due to unmet HSR Act Clearance conditions by the End Date.
- Equity Compensation: Outstanding options, RSUs, and PSUs will be converted into cash (based on the excess of the $17.00 consideration over exercise price, if applicable) and CVRs.
Material Changes and Contingent Value Rights
The filing details the issuance of CVRs, which represent non-tradeable contractual rights to future payments based on the performance of the asset "ampreloxetine." The CVR Payment Amount includes:
- 80% of net proceeds from any license or divestiture of ampreloxetine within 10 years of the Effective Time.
- $50,000,000 upon the first commercial sale of ampreloxetine in the U.S., UK, Spain, France, Germany, or Italy.
- 10% of net sales royalties on a country-by-country basis until the later of the 10th anniversary of the first sale, patent expiration, or loss of exclusivity.
The filing explicitly states there can be no assurance that license proceeds, milestone payments, or royalties will be generated or paid.
Guidance, Outlook, and Risks
Management expects the transaction to close in the second half of 2026. The agreement includes a termination date of December 28, 2026, which may be extended automatically for two three-month periods if certain conditions are met. Key risks include the failure to obtain regulatory approvals (HSR Act Clearance), the inability to secure financing, and the uncertainty regarding the commercial success of ampreloxetine and other product candidates. The filing includes standard forward-looking statement disclaimers regarding the realization of anticipated benefits and milestone payments.
Investor Verification Checklist
- Verify the final terms of the Merger Agreement and CVR Agreement in Exhibit 2.1 and Exhibit 10.1.
- Confirm the status of the $350 million debt commitment from OMERS Life Sciences and any conditions precedent.
- Monitor the timeline for HSR Act Clearance and the Company Requisite Vote (two-thirds shareholder approval).
- Review the specific definitions of "License Proceeds" and "Net Sales" in the CVR Agreement to understand the potential upside.
- Assess the risk that the CVR payments may never materialize if ampreloxetine is not licensed or commercially sold.